Professor Errki Ruoslahti of the University of California Santa Barbara’s Burnham Institute for Medical Research has been awarded $2.8 million to develop ‘Hybrid nanotechnologies for detection and synergistic therapies of breast cancer’.
The research team are developing new diagnostic tools to improve early detection, and reduce unnecessary procedures. This will be achieved through the use of nanoparticles as a contrast agent to aid the detection of tumours, which at present would not be detected by MRI. This would both help to diagnose a tumor and help stage its development.
This highlights the promise of nanomedicine for the future. As nanoparticles can be engineered to perform a diverse set of functions, such as targeting to a tumour for both synergistic diagnostics and treatment by targeting a therapeutic agent with the nanoparticle. – CT